The $2 million investment will help support general operations and the further development of the Company's pipeline of programs. AiVita's active programs currently include a stem cell-based skin care product which helps address several key signs of aging, and a novel cancer immunotherapy applicable to multiple solid tumor types. The Company anticipates a Phase II clinical trial exploring the efficacy of its immunotherapeutic approach in patients with ovarian cancer within the year.
California Technology Ventures holds the right to invest additional funds at a future date.
About AiVita Biomedical
AiVita Biomedical is advancing commercial and clinical-stage programs utilizing curative and regenerative medicines. Built upon expertise in stem cell growth and directed, high-purity differentiation, AiVita Biomedical has engineered safe, efficient and economical manufacturing systems to support the development and commercialization of curative and regenerative medicines. For more information, visit www.aivitabiomedical.com.
Logo - http://photos.prnewswire.com/prnh/20160610/377832LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aivita-biomedical-raises-2m-in-series-a-financing-for-commercial-and-clinical-stage-program-development-300282885.html
SOURCE AiVita Biomedical